New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.
about
Dual Inhibitor AEE788 Reduces Tumor Growth in Preclinical Models of MedulloblastomaPHLiPPing the switch on Akt and protein kinase C signalingKilling cancer with platycodin D through multiple mechanismsTargeting Apoptosis and Multiple Signaling Pathways with Icariside II in Cancer CellsNext-generation clinical trials: Novel strategies to address the challenge of tumor molecular heterogeneityDisabling Mitochondrial Peroxide Metabolism via Combinatorial Targeting of Peroxiredoxin 3 as an Effective Therapeutic Approach for Malignant MesotheliomaGrb7 SH2 domain structure and interactions with a cyclic peptide inhibitor of cancer cell migration and proliferationReview of Cisplatin and oxaliplatin in current immunogenic and monoclonal antibody treatmentsPragmatic medicine in solid cancer: a translational alternative to precision medicineFatty acid esters of phloridzin induce apoptosis of human liver cancer cells through altered gene expressionTargeting vascular endothelial growth factor receptor 2 and protein kinase D1 related pathways by a multiple kinase inhibitor in angiogenesis and inflammation related processes in vitroProdrug AST-003 Improves the Therapeutic Index of the Multi-Targeted Tyrosine Kinase Inhibitor SunitinibDual Inhibition of Topoisomerase II and Tyrosine Kinases by the Novel Bis-Fluoroquinolone Chalcone-Like Derivative HMNE3 in Human Pancreatic Cancer CellsA Dual-Modality System for Both Multi-Color Ultrasound-Switchable Fluorescence and Ultrasound Imaging.Vascular endothelial growth factor as an anti-angiogenic target for cancer therapyPreclinical molecular imaging of tumor angiogenesis.Inferring pathway dysregulation in cancers from multiple types of omic data.Identification of novel small-molecule compounds that inhibit the proproliferative Kruppel-like factor 5 in colorectal cancer cells by high-throughput screeningMolecular characterization of EGFR, PDGFRA and VEGFR2 in cervical adenosquamous carcinoma.Inhibition of protein kinases by anticancer DNA intercalator, 4-butylaminopyrimido[4',5':4,5]thieno(2,3-b)quinolineEpithelial-mesenchymal transition-associated secretory phenotype predicts survival in lung cancer patients.The contribution of a 2-amino group on receptor tyrosine kinase inhibition and antiangiogenic activity in 4-anilinosubstituted pyrrolo[2,3-d]pyrimidinesLyn kinase and ZAP70 are substrates of PTPROt in B-cells: Lyn inactivation by PTPROt sensitizes leukemia cells to VEGF-R inhibitor pazopanibSunitinib in metastatic thymic carcinomas: laboratory findings and initial clinical experience.Targeting proapoptotic protein BAD inhibits survival and self-renewal of cancer stem cellsMEK/ERK inhibitor U0126 increases the radiosensitivity of rhabdomyosarcoma cells in vitro and in vivo by downregulating growth and DNA repair signalsTailoring tyrosine kinase inhibitors to fit the lung cancer genome.Repositioning of Tyrosine Kinase Inhibitors as Antagonists of ATP-Binding Cassette Transporters in Anticancer Drug ResistanceInduction of BCL2-Interacting Killer, BIK, is Mediated for Anti-Cancer Activity of Curcumin in Human Head and Neck Squamous Cell Carcinoma Cells.PET imaging of early response to the tyrosine kinase inhibitor ZD4190.Artesunate suppresses tumor growth and induces apoptosis through the modulation of multiple oncogenic cascades in a chronic myeloid leukemia xenograft mouse model.Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity.Protein kinase C-beta inhibition induces apoptosis and inhibits cell cycle progression in acquired immunodeficiency syndrome-related non-hodgkin lymphoma cellsN⁴-(3-Bromophenyl)-7-(substituted benzyl) pyrrolo[2,3-d]pyrimidines as potent multiple receptor tyrosine kinase inhibitors: design, synthesis, and in vivo evaluation.Tyrosine kinase inhibitors as modulators of ABC transporter-mediated drug resistance.Taxifolin synergizes Andrographolide-induced cell death by attenuation of autophagy and augmentation of caspase dependent and independent cell death in HeLa cells.N2-Trimethylacetyl substituted and unsubstituted-N4-phenylsubstituted-6-(2-pyridin-2-ylethyl)-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamines: design, cellular receptor tyrosine kinase inhibitory activities and in vivo evaluation as antiangiogenic, antimetDesign, synthesis and biological evaluation of substituted pyrrolo[2,3-d]pyrimidines as multiple receptor tyrosine kinase inhibitors and antiangiogenic agentsThe scientific impact of the Structural Genomics Consortium: a protein family and ligand-centered approach to medically-relevant human proteins.Centrosomal PKCbetaII and pericentrin are critical for human prostate cancer growth and angiogenesis.
P2860
Q24615472-7AD4B182-F96B-433C-B7AB-8117FEFCB194Q24625894-A130A412-2973-4FF6-9626-A3A5BEB86C61Q26773408-DF1F491A-68EF-4242-A532-7A9E15803745Q26798203-7B322C0D-8E2B-4D73-AB73-8D8FF4F37C9FQ26992272-CF59DB05-C82F-43B1-A283-6EEC9C8DB61DQ27306784-F57B4833-B0EC-49E6-923A-CDC5E8C887FFQ27648499-5C4BE3F4-9BAC-4748-ABD2-B57659316298Q28082382-E3B7BA25-78BF-40B7-8AF2-12C6AA9D3560Q28391863-CC58C983-2F2C-45F0-AB6C-0F1BC3E5EF45Q28543028-01C92EB0-0CBC-4BA4-BED9-F88C70D99382Q28546317-192EBECF-05A3-4664-BDAB-96AEED41456FQ28550556-9A42DA7D-AA81-411D-9662-CFDC0D81B4B9Q28552765-4B49207E-DC73-4AC7-9C6E-95B106266A82Q30360896-0762AF0A-2544-476F-9049-745C20537E04Q30455612-5AED08C7-0CB9-4F80-A79E-7D240C8FEF42Q30475818-50EB0C9E-959B-45F6-B54E-5CBB4C52577BQ30980125-3480EEA5-1F6E-4511-9123-70848F3E2864Q33412050-0D6CCAE6-4BAF-407B-9BF8-5C653E5A9EBDQ33475963-D3A35703-7024-4368-BEBA-4CEAEB19F382Q33682972-8F2242DA-C33A-42A1-8FC5-0515CCE5466BQ33705213-A68F33A3-A950-4F32-805C-1ACD34F05155Q33835807-2AE5500E-2BC0-4B70-A231-E6BE7CD09DAEQ33952692-F80EF886-BFEB-46FA-A813-B36DC6A8E1C1Q34005875-2E515B18-C42D-4C86-B2A9-6AA8FA1C96EBQ34486457-EA913472-E707-4440-8ECD-30411EBEF1E9Q34721752-B48635CA-7503-4ABB-85AE-5D6006142B03Q34754045-45EA207D-2362-45B5-A49A-5EADC557658EQ34774854-96862E2E-2130-4E22-B717-2593FBBF2ABAQ35148085-EF421D0D-E587-4235-940B-83244BEE5830Q35249646-BC48B37D-3B5B-46C3-A79A-37342B1E4E7AQ35551934-E33D6C1D-0032-4353-B2A8-526E18B09A4CQ35591349-5A6D1311-6AE6-476E-8C68-5ABEE3E1029EQ35634280-C1DAE8DC-51B2-4F16-9967-04ACE7AE18D1Q35848191-501C463C-75F9-439E-9F42-C13292633EFCQ35946822-23A9EE87-C2D2-4642-ACBC-029AFE214C9CQ36275528-415BB0D7-3D61-4F97-B26F-4F85CE3A3945Q36614871-74FF1751-18F5-4E02-9448-C99C560A76A9Q36775982-13C40521-FBDE-409D-89F5-00860E0DE5D9Q36969182-8792EFB9-9BB9-423A-98AB-CF9CDA89AB77Q37003631-375E970F-88BC-4F44-A06D-89CAE40D20C1
P2860
New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
New paradigms in anticancer th ...... thways with kinase inhibitors.
@ast
New paradigms in anticancer th ...... thways with kinase inhibitors.
@en
type
label
New paradigms in anticancer th ...... thways with kinase inhibitors.
@ast
New paradigms in anticancer th ...... thways with kinase inhibitors.
@en
prefLabel
New paradigms in anticancer th ...... thways with kinase inhibitors.
@ast
New paradigms in anticancer th ...... thways with kinase inhibitors.
@en
P1433
P1476
New paradigms in anticancer th ...... athways with kinase inhibitors
@en
P2093
Eric Raymond
Siham Djelloul
P304
P356
10.1053/J.SEMINONCOL.2006.04.005
P577
2006-08-01T00:00:00Z